Pamela Carroll '85 uses AI in biotechnology to tackle formerly “undruggable” drivers of disease

The most expensive AI mistake isn't buying the wrong tool. It's buying a tool without a clear problem to solve first. A biotech executive named Pamela Carroll is using AI to crack diseases that wer

The most expensive AI mistake isn't buying the wrong tool.

It's buying a tool without a clear problem to solve first.


A biotech executive named Pamela Carroll is using AI to crack diseases that were previously considered unsolvable. Not because she found the flashiest platform. Because her team got laser-focused on one specific problem and chose AI that fit that problem exactly.

That's the part nobody talks about.


You've probably been sold on features — dashboards, automation, integrations. But if your team never opens the tool, the features don't matter. The $200/month just quietly disappears.

The issue isn't the technology. It's that nobody defined what "working" actually looks like before the purchase.


Here's what actually works: pick one repetitive task your team complains about weekly. Just one. Then ask what a solved version of that looks like in 30 days. That single constraint will tell you more about which AI tool you need than any demo ever will.

Start with the problem. Let the tool follow.


What's one task in your business you keep saying AI should be able to handle — but you haven't pulled the trigger yet?

#AIstrategy #BusinessGrowth #SmallBusiness #AIImplementation

Original Source

To succeed, the next generation of biotech will leverage AI tools and deep data integration, enabling scientists to have a singular focus on solving ...